Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

229
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chamber-specific chromatin architecture guides functional interpretation of disease-associated Cis-regulatory elements in human cardiomyocytes.

Nature communications·2026
Same author

Outcome after ablation of atypical atrial flutter: Is induction a feasible approach?

International journal of cardiology. Heart & vasculature·2024
Same author

PET/CT-identified atrial hypermetabolism is an index of atrial inflammation in patients with atrial fibrillation.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2023
Same author

Role of catheter location on local impedance measurements and clinical outcome with the new direct sense technology in cardiac ablation procedures.

International journal of cardiology. Heart & vasculature·2022
Same author

Stroke prevention of atrial fibrillation: Improving geographic under-use of contemporary antithrombotic approaches remains a challenge.

International journal of cardiology. Heart & vasculature·2021
Same author

Significance of myeloperoxidase plasma levels as a predictor for cardiac resynchronization therapy response.

Clinical research in cardiology : official journal of the German Cardiac Society·2020

Related Experiment Video

Updated: May 1, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

[Cardiovascular pharmacotherapy. Risks and adverse effects].

N Voigt1, J Heijman, D Dobrev

  • 1Institut für Pharmakologie, Medizinische Fakultät, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Deutschland.

Herz
|April 3, 2014
PubMed
Summary
This summary is machine-generated.

Adverse drug reactions from cardiovascular medications are common and serious. Understanding factors like patient age and drug interactions helps minimize these dangerous side effects.

Related Experiment Videos

Last Updated: May 1, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

7.9K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Safety

Context:

  • Adverse drug side effects are a significant issue in healthcare.
  • Cardiovascular drugs are widely prescribed, increasing potential for adverse events.
  • Patient-specific factors and drug interactions complicate drug safety.

Purpose:

  • To review common adverse side effects of cardiovascular drugs.
  • To identify factors contributing to these side effects in patients.
  • To enhance understanding of cardiovascular drug risks.

Summary:

  • This review details adverse side effects of cardiovascular drugs, focusing on factors like reduced hepatic/renal clearance in elderly patients and pharmacokinetic/pharmacodynamic interactions.
  • Key cardiac side effects discussed include arrhythmias, AV block, long-QT syndrome, torsade de pointes, and altered inotropy.
  • Non-cardiac side effects are categorized by drug class.

Impact:

  • Improved understanding of cardiovascular drug risks can reduce patient mortality and morbidity.
  • Optimizing drug dosage and managing interactions can mitigate adverse events.
  • This knowledge supports safer prescribing practices for cardiovascular medications.